AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9744590 — intervention group
Group type: COMPARATOR
Intervention: Fleet Phospho‐soda
Number of subjects: 194
Study 8118746 — intervention group
Group type: EXPERIMENTAL
Intervention: sCT 100 IU/6 times a week
Number of subjects: 54
Study 8118746 — intervention group
Group type: EXPERIMENTAL
Intervention: sCT 200 IU/3 times a week
Number of subjects: 54
Study 8118746 — intervention group
Group type: COMPARATOR
Intervention: Placebo/6 times a week
Number of subjects: 54
Study 3281057 — intervention group
Group type: EXPERIMENTAL
Intervention: RS‐86 (10 mg/d) plus glycopyrrolate (6 mg/d)
Number of subjects: 7
Study 3281057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30898129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-PCMHI delivered by clinical staff in routine care settings
Number of subjects: 6
Study 30898129 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6
Study 29142966 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental Mg 30 mmol/d
Number of subjects: 36
Study 29142966 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental Mg 15 mmol/d
Number of subjects: 36
Study 29142966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 26651828 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo treatment (EXP)
Number of subjects: 62
Study 26651828 — intervention group
Group type: COMPARATOR
Intervention: Graded activity treatment (GA)
Number of subjects: 62
Study 22258209 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwifruit (3 kiwifruits per day)
Number of subjects: 102
Study 22258209 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-rich diet
Number of subjects: 102
Study 22258209 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 20946333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab 1.25 mg/0.05 ml
Number of subjects: 12
Study 20946333 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes (control)
Number of subjects: 12
Study 18692170 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate/behavioural treatment (BT)
Number of subjects: 90
Study 18692170 — intervention group
Group type: COMPARATOR
Intervention: methylphenidate-only
Number of subjects: 90
Study 16822823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragaglitazar
Number of subjects: 345
Study 12588583 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk + (home-based pedometer-driven walking program with arthritis self-management education)
Number of subjects: 34
Study 12588583 — intervention group
Group type: COMPARATOR
Intervention: EDU (arthritis self-management education alone)
Number of subjects: 34
Study 12588583 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk +
Number of subjects: 34
Study 12588583 — intervention group
Group type: COMPARATOR
Intervention: EDU
Number of subjects: 34
Study 11090798 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (angiotensin-converting enzyme inhibitor)
Number of subjects: 30
Study 11090798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8923865 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (IGF-I) 60 micrograms/kg
Number of subjects: 8
Study 1482187 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncooked vegan diet for 1 month
Number of subjects: 18
Study 1482187 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet
Number of subjects: 18
Study 3977582 — intervention group
Group type: EXPERIMENTAL
Intervention: Kegel's exercises (vaginal musculature contractions)
Number of subjects: 30
Study 3977582 — intervention group
Group type: EXPERIMENTAL
Intervention: Kegel's exercises with self-generated fantasy
Number of subjects: 30
Study 3977582 — intervention group
Group type: EXPERIMENTAL
Intervention: Kegel's exercises (after 1 week of practice)
Number of subjects: 30
Study 3977582 — intervention group
Group type: COMPARATOR
Intervention: Informed about Kegel's exercises but did not practice
Number of subjects: 30
Study 3977582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information about Kegel's exercises)
Number of subjects: 30
Study 30676012 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswellia serrata lecithin-based delivery form (Casperome®) - one tablet/day
Number of subjects: 69
Study 30676012 — intervention group
Group type: COMPARATOR
Intervention: Standard management (SM) group: diet and, if needed, hyoscine butylbromide (Buscopan®) or papaverine hydrochloride + 10 mg of Atropa belladonna extract
Number of subjects: 69
Study 30676012 — intervention group
Group type: COMPARATOR
Intervention: Standard management (SM) group
Number of subjects: 69
Study 29738346 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat group (56g/day of lean red meat added)
Number of subjects: 180
Study 29738346 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 27523046 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + LLLT
Number of subjects: 25
Study 27523046 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 25
Study 24494593 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted self-management
Number of subjects: 392
Study 24494593 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted self-management plus problem-solving therapy
Number of subjects: 392
Study 24494593 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education
Number of subjects: 392
Study 24494593 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 392
Study 24246458 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC)
Number of subjects: 38
Study 24246458 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 38
Study 24246458 — intervention group
Group type: EXPERIMENTAL
Intervention: Both KC and SC
Number of subjects: 38
Study 20735289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV)
Number of subjects: 16
Study 20735289 — intervention group
Group type: COMPARATOR
Intervention: Immunomodulatory therapy (IMT)
Number of subjects: 16
Study 19052246 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm ergometer therapy (n = 10)
Number of subjects: 30
Study 19052246 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic therapy (n = 10)
Number of subjects: 30
Study 19052246 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy (OT) group (control) (n = 10)
Number of subjects: 30
Study 15705982 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin drug therapy initiation protocol at hospital discharge
Number of subjects: 403
Study 15705982 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin drug therapy initiation protocol
Number of subjects: 403
Study 15705982 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (no statin initiation protocol)
Number of subjects: 403
Study 12907105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg) administered intravenously 1 hour after surgery
Number of subjects: 90
Study 12907105 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously 1 hour after surgery
Number of subjects: 90
Study 10603730 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms iodine/d
Number of subjects: 262
Study 10603730 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms iodine/d
Number of subjects: 262
Study 10603730 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg iodine/week
Number of subjects: 262
Study 10603730 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms iodine/d plus 75 to 100 micrograms T4/d
Number of subjects: 262
Study 10603730 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms iodine plus 100 micrograms T4/d
Number of subjects: 262
Study 10603730 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined iodine/T4 treatment
Number of subjects: 262
Study 10603730 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-T4 therapy
Number of subjects: 262
Study 10603730 — intervention group
Group type: COMPARATOR
Intervention: Healthy people
Number of subjects: 262
Study 10603730 — intervention group
Group type: COMPARATOR
Intervention: Patients with goitre
Number of subjects: 262
Study 10603730 — intervention group
Group type: COMPARATOR
Intervention: Patients with nodular goitres
Number of subjects: 262
Study 7573726 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 88
Study 7573726 — intervention group
Group type: COMPARATOR
Intervention: Melphalan
Number of subjects: 88
Study 2045382 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated plasmapheresis prior to pulse cyclophosphamide
Number of subjects: 0
Study 2045382 — intervention group
Group type: COMPARATOR
Intervention: Pulse cyclophosphamide alone
Number of subjects: 0
Study 7002482 — intervention group
Group type: COMPARATOR
Intervention: Tolmetin sodium (1600 mg daily)
Number of subjects: 46
Study 7002482 — intervention group
Group type: COMPARATOR
Intervention: Aloxiprin (initially 6 g daily, reduced to 4 g daily after 3 months)
Number of subjects: 46
Study 7002482 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone (400 mg daily)
Number of subjects: 46
Study 31208778 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperPath approach
Number of subjects: 100
Study 31208778 — intervention group
Group type: COMPARATOR
Intervention: Traditional posterior approach
Number of subjects: 100
Study 27806023 — intervention group
Group type: EXPERIMENTAL
Intervention: Core depressive symptoms
Number of subjects: 267
Study 27806023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep symptoms
Number of subjects: 267
Study 25763792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification Program (LMP)
Number of subjects: 104
Study 25763792 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 104
Study 23179365 — intervention group
Group type: EXPERIMENTAL
Intervention: LINE-1 hypomethylation
Number of subjects: 203
Study 21545385 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + HSGS
Number of subjects: 147
Study 21545385 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only
Number of subjects: 147
Study 21545385 — intervention group
Group type: EXPERIMENTAL
Intervention: HSGS only
Number of subjects: 147
Study 21545385 — intervention group
Group type: COMPARATOR
Intervention: Education group
Number of subjects: 147
Study 18613809 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (≤ 250 mg/day)
Number of subjects: 0
Study 18613809 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 0
Study 18613809 — intervention group
Group type: COMPARATOR
Intervention: Placebo or index groups
Number of subjects: 0
Study 16792607 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-through-needle technique
Number of subjects: 116
Study 16792607 — intervention group
Group type: COMPARATOR
Intervention: Double segment technique
Number of subjects: 116
Study 12680734 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 28
Study 12680734 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 28
Study 10636129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 462
Study 10636129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 1384304 — intervention group
Group type: EXPERIMENTAL
Intervention: Almokalant 4.5 mg intravenously over 10 minutes
Number of subjects: 10
Study 1384304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3925972 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 12
Study 3925972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30967649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent letrozole
Number of subjects: 956
Study 30967649 — intervention group
Group type: COMPARATOR
Intervention: Continuous letrozole
Number of subjects: 956
Study 30232642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ovulatory follicular fluid (FF) levels of soluble urokinase plasminogen activator receptor (suPAR) in women with severe OHSS (n = 25)
Number of subjects: 1050
Study 30232642 — intervention group
Group type: COMPARATOR
Intervention: Pre-ovulatory follicular fluid (FF) levels of soluble urokinase plasminogen activator receptor (suPAR) in high-risk controls (n = 25)
Number of subjects: 1050
Study 30232642 — intervention group
Group type: COMPARATOR
Intervention: Pre-ovulatory follicular fluid (FF) levels of soluble urokinase plasminogen activator receptor (suPAR) in low-risk controls (n = 25)
Number of subjects: 1050
Study 30232642 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis for suPAR levels predicting severe OHSS
Number of subjects: 1050
Study 27902713 — intervention group
Group type: EXPERIMENTAL
Intervention: GlycA (N-acetyl glycan groups attached to acute phase proteins)
Number of subjects: 34320
Study 27902713 — intervention group
Group type: EXPERIMENTAL
Intervention: GlycA
Number of subjects: 34320
Study 27902713 — intervention group
Group type: COMPARATOR
Intervention: hsCRP, fibrinogen, and sICAM-1
Number of subjects: 34320
Study 24607076 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxic solution (ionic hydroxylamine hydrochloride at 9mg/ml)
Number of subjects: 51
Study 24607076 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 51
Study 24607076 — intervention group
Group type: COMPARATOR
Intervention: Hand dynamometer (no kinesiologist present)
Number of subjects: 51
Study 24607076 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiologist 1
Number of subjects: 51
Study 24607076 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiologist 2
Number of subjects: 51
Study 24607076 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiologist 3
Number of subjects: 51
Study 24607076 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison (female kinesiologists)
Number of subjects: 51
Study 24607076 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in AK test effectiveness
Number of subjects: 51
Study 24607076 — intervention group
Group type: EXPERIMENTAL
Intervention: Time perception
Number of subjects: 51
Study 22459183 — intervention group
Group type: EXPERIMENTAL
Intervention: 75°C CRF for 120 s to 180 s (SCRF group)
Number of subjects: 60
Study 22459183 — intervention group
Group type: EXPERIMENTAL
Intervention: 75°C CRF for 240 s to 300 s (LCRF group)
Number of subjects: 60
Study 22459183 — intervention group
Group type: EXPERIMENTAL
Intervention: 42°C PRF for 10 minutes followed by 75°C CRF for 120 s to 180 s (PCRF group)
Number of subjects: 60
Study 19653815 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (30/120/180 mg every 4 weeks or 60/180 mg every 12 weeks)
Number of subjects: 366
Study 19653815 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 366
Study 19653815 — intervention group
Group type: COMPARATOR
Intervention: IV BP
Number of subjects: 366
Study 18404583 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS approach (mini-midvastus approach)
Number of subjects: 60
Study 18404583 — intervention group
Group type: COMPARATOR
Intervention: Control group (midvastus approach)
Number of subjects: 60
Study 16094573 — intervention group
Group type: EXPERIMENTAL
Intervention: Creating a subperiosteal tunnel before lateral osteotomy
Number of subjects: 18
Study 16094573 — intervention group
Group type: COMPARATOR
Intervention: Not creating a subperiosteal tunnel (Control)
Number of subjects: 18
Study 12108909 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography (echo)
Number of subjects: 70
Study 12108909 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide ventriculography (RNV)
Number of subjects: 70
Study 12108909 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 70
Study 10402691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 76
Study 8892171 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (100 IU/day)
Number of subjects: 35
Study 8892171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 1538156 — intervention group
Group type: EXPERIMENTAL
Intervention: NG-mononmethyl-L-arginine (NMA)
Number of subjects: 0
Study 1538156 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginase
Number of subjects: 0
Study 1538156 — intervention group
Group type: COMPARATOR
Intervention: IFN-gamma stimulated mouse peritoneal macrophages
Number of subjects: 0
Study 1538156 — intervention group
Group type: COMPARATOR
Intervention: Activated mouse macrophages
Number of subjects: 0
Study 6339105 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (240 mg)
Number of subjects: 16
Study 6339105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31910496 — intervention group
Group type: EXPERIMENTAL
Intervention: UHR individuals with remission from the UHR state at 12-month follow-up (n=33, 36%)
Number of subjects: 146
Study 31910496 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline functioning
Number of subjects: 146
Study 30791824 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban (37.5 mg total dose)
Number of subjects: 204
Study 30791824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 30027297 — intervention group
Group type: EXPERIMENTAL
Intervention: Thao‐Child Health Program (TCHP) intervention
Number of subjects: 2250
Study 30027297 — intervention group
Group type: COMPARATOR
Intervention: Usual health care policy (Control)
Number of subjects: 2250
Study 26822461 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group exercise therapy
Number of subjects: 102
Study 26822461 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise therapy
Number of subjects: 102
Study 24641549 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition heuristic applied by groups
Number of subjects: 43
Study 24641549 — intervention group
Group type: EXPERIMENTAL
Intervention: Time constraints
Number of subjects: 43
Study 22472585 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges (Lactobacillus reuteri DSM 17938 and ATCC PTA 5289), 2/day for 6 weeks
Number of subjects: 62
Study 22472585 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 62
Study 19959243 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 6
Study 17674398 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCI Severity Scale
Number of subjects: 113
Study 17674398 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCI Symptom Checklist
Number of subjects: 113
Study 15650887 — intervention group
Group type: COMPARATOR
Intervention: Pretension at 0% MVC
Number of subjects: 10
Study 15650887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretension at 30% MVC
Number of subjects: 10
Study 15650887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretension at 60% MVC
Number of subjects: 10
Study 15650887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretension at 90% MVC
Number of subjects: 10
Study 15650887 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG activity (agonist and antagonist)
Number of subjects: 10
Study 12404190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combined hormone‐replacement therapy (HRT) - conjugated equine estrogen 0.625 mg/d for 28 days and 5 mg of medroxyprogesterone acetate during the last 14 days
Number of subjects: 30
Study 12404190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10023944 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (5 MU, 5 MU, 10 MU for the first week, then 10 MU three times per week for 11 weeks)
Number of subjects: 335
Study 10023944 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (300 mg once daily for 12 weeks)
Number of subjects: 335
Study 7775624 — intervention group
Group type: EXPERIMENTAL
Intervention: Local intraarterial infusion of 25 micrograms/h somatostatin
Number of subjects: 6
Study 7775624 — intervention group
Group type: COMPARATOR
Intervention: Systemic control infusion
Number of subjects: 6
Study 1651741 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy followed by prophylactic cranial irradiation (PCI) for disease-free patients
Number of subjects: 146
Study 1651741 — intervention group
Group type: EXPERIMENTAL
Intervention: N0 disease patients
Number of subjects: 146
Study 1651741 — intervention group
Group type: EXPERIMENTAL
Intervention: N1 disease patients
Number of subjects: 146
Study 1651741 — intervention group
Group type: EXPERIMENTAL
Intervention: N2 disease patients
Number of subjects: 146
Study 1651741 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving PCI
Number of subjects: 146
Study 6130666 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of beta-receptor blockers
Number of subjects: 48
Study 6130666 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of beta-receptor blockers
Number of subjects: 48
Study 31351829 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention program (9-session hands-on intervention)
Number of subjects: 80
Study 31351829 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 80
Study 28983903 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound-guided short-axis needle tip navigation technique
Number of subjects: 102
Study 28983903 — intervention group
Group type: COMPARATOR
Intervention: Landmark technique
Number of subjects: 102
Study 27552592 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplements (1,470mg DHA and 147mg EPA daily for 12 weeks)
Number of subjects: 110
Study 24393602 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab Early regimen (Weeks 0, 1, 2, 4)
Number of subjects: 435
Study 24393602 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab Monthly regimen (Weeks 0, 4, 8)
Number of subjects: 435
Study 24393602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study 21526339 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression leggings
Number of subjects: 12
Study 19087000 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 0
Study 19087000 — intervention group
Group type: COMPARATOR
Intervention: 0.5% levobupivacaine
Number of subjects: 0